Galectin Therapeutics is working to improve the lives of patients with MASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE clinical study in MASH cirrhosis.
News
-
07/09/25
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 -
06/10/25
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension -
05/15/25
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
Who We Are
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Learn MoreWhat We Do
Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
Learn MoreWho We Help
The lead development program is in non‑alcoholic steatohepatitis (MASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Learn More